Biocept and UC San Diego Moores Cancer Center Announce Collaboration to Study Feasibility of Liquid Biopsy to Predict Disease Recurrence in Solid Tumors and Response to Therapy
The first study is designed to determine the feasibility of using liquid biopsy to predict disease recurrence in patients with Stage II or III cancer at high risk for recurrence. The second study will evaluate the feasibility of using liquid biopsy to predict response to therapy in patients with metastatic solid tumors. The studies are designed to evaluate
"Despite recent advances in chemotherapy and radiation, risk for post-resection disease recurrence in patients with stage II or stage III solid tumors remains unacceptably high," said
"We are enthusiastic about working with
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the outcomes of patients diagnosed with cancer, the results of the clinical studies and ability to use circulating tumor cells in disease assessment, surveillance and monitoring, and our ability to enable more rapid and comprehensive treatment options for patients diagnosed with cancer, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
View original content with multimedia:http://www.prnewswire.com/news-releases/biocept-and-uc-san-diego-moores-cancer-center-announce-collaboration-to-study-feasibility-of-liquid-biopsy-to-predict-disease-recurrence-in-solid-tumors-and-response-to-therapy-300684663.html
SOURCE
Investor Contact: LHA Investor Relations, Jody Cain, Jcain@lhai.com, 310-691-7100, OR Media Contact: Trevelino/Keller, Colleen Murphy, cmurphy@trevelinokeller.com, 404-214-0722, Ext. 109